BioSpace News Archive

BIOREM Inc. today announced its results for the three and six-month periods ended June 30, 2023.

Mallinckrodt plc announced it has entered into a Restructuring Support Agreement with a substantial majority of each of the Company’s first and second lien debtholders and the Opioid Master Disbursement Trust II on the terms of a comprehensive financial restructuring plan that will reduce the Company’s total funded debt by approximately $1.9 billion, increase free cash flow generation, extend maturity runway and better position the business for long-term success.

Adial Pharmaceuticals, Inc. announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

ABVC BioPharma, Inc today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company’s ADHD Phase IIb clinical study.

Pyxis Oncology today announced the successful completion of its acquisition of Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million.